{
  "id": "ic-a1",
  "version": "1",
  "drug": {
    "slug": "glp-1-agonists",
    "display": "GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)"
  },
  "supplement": {
    "slug": "berberine",
    "display": "Berberine"
  },
  "severity": "moderate",
  "evidenceTier": "pharmacology-standard",
  "mechanism": "Both lower blood glucose through different pathways: GLP-1 agonists via the incretin signal and appetite, berberine via insulin sensitivity and AMPK. The concern is additive glucose lowering, primarily when insulin or a sulfonylurea is also part of the regimen.",
  "patientNotes": [
    "Do not add berberine on top of a GLP-1 medication without telling your prescriber.",
    "If your doctor approves, glucose monitoring may need to be more frequent."
  ],
  "pmids": [
    "41543854"
  ],
  "pubmedUrls": [
    "https://pubmed.ncbi.nlm.nih.gov/41543854/"
  ],
  "guideSlugs": [
    "berberine-with-semaglutide",
    "berberine-vs-ozempic",
    "glp-1-companion-supplements"
  ],
  "guideUrls": [
    "https://supplementbrief.com/berberine-with-semaglutide/",
    "https://supplementbrief.com/berberine-vs-ozempic/",
    "https://supplementbrief.com/glp-1-companion-supplements/"
  ],
  "pairUrl": "https://supplementbrief.com/interactions/glp-1-agonists/berberine/",
  "reviewedBy": "natallia-kalistratava",
  "reviewerUrl": "https://supplementbrief.com/authors/natallia-kalistratava/",
  "lastVerified": "2026-09-05",
  "jsonUrl": "https://supplementbrief.com/data/v1/pairs/ic-a1.json",
  "htmlUrl": "https://supplementbrief.com/data/v1/pairs/ic-a1/"
}
